Transplantation of Islet Organoids into Brown Adipose Tissue in a Diabetic Mouse Model.
Sun A., Singh M., Bamrah M., Li W., Aguirre A., Wang P.
Prospective Study on Type 1 Diabetes, Autoimmune Research, published in Methods Mol Biol (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Methods Mol Biol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39702860
- DOI
- 10.1007/7651_2024_588
Abstract (original English)
Pancreatic islet transplantation is a promising cell replacement therapy for patients with type 1 diabetes (T1D), an autoimmune disease that destroys insulin-producing islet β cells. However, the shortage of donor pancreatic islets significantly limits the widespread use of this strategy as a routine therapy. Pluripotent stem cell-derived insulin-producing islet organoids present a promising alternative β cell source for T1D patients. One critical challenge is the lack of vascularization in islet organoids, making it essential to investigate vascularized transplantation sites to support their survival. Brown adipose tissue (BAT) is well vascularized and secretes active cytokines, facilitating islet organoid survival. Thus, BAT represents a promising transplantation site for islet organoids, making it an ideal location to support cell replacement therapies and improve treatment approaches for T1D. Here, we describe the methods for transplanting human-induced pluripotent stem cell (iPSC)-derived islet organoids into the BAT of a mouse model.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Transforming hypoglycemia prediction in adult type 1 diabetes: a systematic review and meta-analysis for precision care
Meta-analysis on Type 1 Diabetes, published in Open Life Sci (2026) — summary generated from the PubMed abstract.
- 2026
Open Life Sci - Level ASystematic ReviewEurope PMC
Long-term storage, cryopreservation, and culture of isolated human islets: a systematic review
Systematic Review on Type 1 Diabetes, published in Front Transplant (2025) — summary generated from the PubMed abstract.
- 2025
Front Transplant - Level AMeta-analysisEurope PMC
Change in Viability and Function of Pancreatic Islets after Coculture with Mesenchymal Stromal Cells: A Systemic Review and Meta-Analysis
Meta-analysis on Type 1 Diabetes, published in J Diabetes Res (2020) — summary generated from the PubMed abstract.
- 2020
J Diabetes Res7 citations - Level AMeta-analysisEurope PMC
Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits
Meta-analysis on Type 1 Diabetes, Type 2 Diabetes, published in Stem Cell Investig (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cell Investig22 citations - Level AMeta-analysisEurope PMC
Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis
Meta-analysis with a reported sample of 524 on Type 1 Diabetes, published in PLoS One (2016) — summary generated from the PubMed abstract.
- 2016
- n = 524
PLoS One81 citations - Level BClinical TrialEurope PMC
Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment
Clinical Trial on Type 1 Diabetes, Type 2 Diabetes, Scar, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells1 citations